National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Enzalutamide (Xtandi®) is indicated for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.

Rapid Review

Commenced Completed Outcome
28/06/2013 10/07/2013 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
30/10/2013 initial
06/12/2013 updated
 10/04/2014 Reimbursement not Recommended

In October 2013, Astellas Pharma Co Ltd submitted an economic evaluation on the cost effectiveness of enzalutamide for this indication.  An updated dossier was submitted on the 6th December 2013.

The NCPE believe that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant cancer whose disease has progressed on or after docetaxel.

Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.